Unicycive Therapeutics (UNCY) 25th Annual Needham Virtual Healthcare Conference summary

Key product and clinical updates

• Lead drug oxylanthanum carbonate (OLC) targets hyperphosphatemia in dialysis patients, with a PDUFA date in June and commercial launch preparations underway.

• OLC aims to reduce pill burden, offering a potent, swallowable tablet with patent protection through 2035.

• Clinical trials showed 31% improvement in patients achieving target phosphate levels, with 69% managed on one pill three times daily.

• Adverse events were mainly mild GI issues, and patient-reported outcomes favored the new therapy.

• The company also has a second drug, UNI-494, in clinical trials for acute kidney injury.

Market landscape and commercialization strategy

• Hyperphosphatemia affects a large dialysis population, with 75% of patients unable to reach target phosphate levels on current therapies.

• OLC is positioned to displace Renvela, the market leader, and calcium-based drugs, addressing unmet needs in efficacy and tolerability.

• The U.S. market is concentrated, with 2,100 physicians prescribing 50% of phosphate binders, enabling a focused sales approach.

• Two-thirds of patients are covered by CMS, and the company is building a hub service for seamless reimbursement.

• Discussions with major dialysis organizations (Fresenius, DaVita) are ongoing, with partnerships expected post-approval.

Regulatory and reimbursement environment

• Previous FDA complete response letter was due to a packaging vendor issue, now resolved; NDA resubmitted and accepted.

• OLC will be available in three tablet strengths (500 mg, 750 mg, 1,000 mg) and is expected to receive first-line approval.

• Medicare reimbursement shifted from Part D to Part B, with TDAPA providing favorable reimbursement for new drugs.

• The company plans to launch OLC before formal TDAPA approval, leveraging commercial insurance for initial access.

• Legislative efforts may extend TDAPA coverage from two to three years, potentially increasing upside.